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Abstract 
A novel carbonylative approach to the synthesis of functionalized 1H-benzo[d]imidazo[1,2-a]imidazoles is 
presented. The method consists in the oxidative aminocarbonylation of N-substituted-1-(prop-2-yn-1-yl)-1H-
benzo[d]imidazol-2-amines, carried out in the presence of secondary nucleophilic amines, to give the 
corresponding alkynylamide intermediates, followed by in situ conjugated addition and double bond 
isomerization, to give 2-(1-alkyl-1H-benzo[d]imidazo[1,2-a]imidazol-2-yl)acetamides. Products were 
obtained in good to excellent yields (64-96%) and high turnover numbers (192-288 mol of product per mol 
of catalyst) under relatively mild conditions (100 °C under 20 atm of a 4:1 mixture of CO-air), using a simple 
catalytic system, consisting of PdI2 (0.33 mol%) in conjunction with KI (0.33 equiv). 
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Introduction 
1H-benzo[d]imidazo[1,2-a]imidazoles are an important class of polyheterocyclic derivatives, which display a 
wide range of pharmacological properties, including analgesic, anti-inflammatory, hypotensive, anti-
aggregant, hypoglycemic and anti-cancer activities.1 Although several methods for the preparation of these 
compounds are currently known,2 the possibility to obtain functionalized 1H-benzo[d]imidazo[1,2-
a]imidazole derivatives in one step by a catalytic multicomponent approach, starting from simple and/or 
readily available building blocks, is still of high synthetic interest. 
 In this Note, we report a novel carbonylative approach3 to the direct synthesis of functionalized 
benzimidazoimidazoles, that are, N,N-dialkyl-2-(1-alkyl-1H-benzo[d]imidazo[1,2-a]imidazol-2-yl)acetamides 
3, starting from N-substituted-1-(prop-2-yn-1-yl)-1H-benzo[d]imidazol-2-amines 1 (Equation 1) Our method 
is based on PdI2/KI-catalyzed4 oxidative monoaminocarbonylation-heterocyclization of 1, carried out in the 
presence of a nucleophilic secondary amine 2 as the external nucleophile and oxygen as the oxidant, and 
allows the direct synthesis of polyheterocyclic derivatives 3 in good to excellent yields in a multicomponent 
fashion under relatively mild conditions (Equation 1) 
 
 
 
 
 
Results and Discussion 
PdI2-KI catalyzed sequential oxidative monoaminocarbomylation of the triple bond followed by 
heterocyclization has emerged as a powerful method for the direct synthesis of carbonylated hetero- or 
carbocycles starting from readily acetylenic substrates bearing a suitably placed hetero- or carbo-
nucleophile.4a,5 The process, carried out in the presence of a secondary amine as external nucleophile and 
oxygen as external oxidant, starts with the formation of an alkynylapalladium species from the reaction 
between the substrate triple bond and PdI2, with the amine acting as a base (Scheme 1). After CO insertion 
and nucleophilic displacement by the amine (now acting as nucleophile), an alkynylamide intermediate is 
formed, from which the final product is produced by in situ intramolecular conjugate addition (Scheme 1; in 
this and in the following Schemes anionic palladium ligands are omitted for clarity) 
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Scheme 1. PdI2/KI-catalyzed sequential oxidative aminocarbonylation of terminal trible bond followed by 
intramolecular conjugate addition leading to heter- or carbocyclic derivatives (YH = nucleophilic group) 
 
 
 In this paper, this kind of chemistry has been applied to the direct carbonylative synthesis of N,N-dialkyl-
2-(1-alkyl-1H-benzo[d]imidazo[1,2-a]imidazol-2-yl)acetamides 3, starting from N-substituted-1-(prop-2-yn-
1-yl)-1H-benzo[d]imidazol-2-amines 1 (readily available by propargylation of 1H-benzo[d]imidazole-2-
amines)6 and amines 2. According to Scheme 2, heterocyclization of the 2-alkynylamide intermediate I by 
intramolecular conjugate addition of the amino group at C-2 to the triple bond followed by double bond 
isomerization would afford the desired products 3. 
 
 
Scheme 2. Work hypothesis: PdI2/KI-catalyzed sequential oxidative aminocarbonylation-conjugate addition-
isomerization leading to N,N-dialkyl-2-(1-alkyl-1H-benzo[d]imidazo[1,2-a]imidazol-2-yl)acetamides 3, 
starting from N-substituted-1-(prop-2-yn-1-yl)-1H-benzo[d]imidazol-2-amines 1 
 
 Initial studies were focused on the reaction of N-methyl-1-(prop-2-yn-1-yl)-1H-benzo[d]imidazol-2-amine 
1a, carried out in the presence of PdI2 (0.33 mol %), KI (0.33 equiv), Et2NH 2a (5 equiv), CO (16 atm) and air 
(4 atm).7 After 6 h, according to our work hypothesis, analysis of the reaction mixture revealed the formation 
of N,N-diethyl-2-(1-methyl-1H-benzo[d]imidazo[1,2-a]imidazol-2-yl)acetamide 3aa, which was isolated in 
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75% yield based on starting 1a, at 85% substrate conversion (Table 1, entry 1). Although this yield was already 
quite satisfactory, an optimization study on reactions conditions was carried out; the results obtained are 
shown in Table 1. As can be seen from Table 1, the best conditions with respect to 3aa yield corresponded 
to those reported in entry 14, that are: PdI2:KI:1a:2a molar ratio = 1:100:300:900, MeCN as the solvent at 
100 °C for 24 h under 20 atm (at 25 °C) of a 4:1 CO-air mixture. In fact, under these optimized conditions, the 
3aa yield was practically quantitative (97% by GLC, 95% isolated). 
 
 
Table 1. PdI2-Catalyzed Oxidative Aminocarbonylation-Heterocyclization-Isomerization of N-methyl-1-
(Prop-2-yn-1-yl)-1H-benzo[d]imidazol-2-amine 1a Under Different Conditionsa. 
 
Entry Solvent PdI2:KI:1a:2a molar 
ratio 
T (°C) t (h) Conversion 
of 1ab (%) 
Yield of 3aac (%) 
1 MeCN 1:100:300:1500 100 6 85 (76) 78 (75) 
2 DME 1:100:300:1500 100 6 69 67 
3 dioxane 1:100:300:1500 100 6 63 60 
4 MeOH 1:100:300:1500 100 6 55 52 
5 MeCN 1:50:300:1500 100 6 72 36 
6 MeCN 1:300:300:15000 100 6 81 74 
7 MeCN 1:100:300:300 100 6 65 39 
8 CH3CN 1:100:300:600 100 6 84 76 
9 MeCN 1:100:300:900 100 6 86 83 
10 MeCN 1:100:300:1500 80 6 60 56 
11 MeCN 1:100:500:2500 100 6 64 58 
12 MeCN 1:100:300:900 100 6 86 82 
5 
 
13 MeCN 1:100:300:900 100 15 95 93 
14 MeCN 1:100:300:900 100 24 100 97 (95) 
a Unless otherwise noted, all reactions were carried out with a substrate concentration of 0.1 mmol of 1a per mL of solvent under 20 atm (at 25 °C) 
of a 4:1 mixture of CO-air. b GLC conversion (isolated conversio) based on starting 1a.  c GLC yields (isolated yield) based on starting 1a. 
 
 
 
Under the optimized conditions, other differently substituted substrates, bearing electron-releasing or 
electron-withdrawing groups on the benzene ring, were smoothly converted into the corresponding 
benzimidazoimidazole derivatives , as shown by the results reported in Table 2, entries 2 (1b, R2 = Me; 3ba 
yield 78%) and 3 (1c, R2 = Cl; 3ca yield 79%). Good product yields were also observed in the case of N-
substituted-1-(prop-2-yn-1-yl)-1H-benzo[d]imidazol-2-amines bearing an alkyl substituent on the amino 
group at C-2 different from methyl, as shown in Table 2, entries 4 (1d, R1 = propyl; 3da yield 78%), 5 (1e, R1 = 
benzyl, 3ea yield 64%), and 6 (1f, R1 = isopentyl, 3fa yield 94%). On the other hand, the use of different 
nucleophilic secondary amines, such as dibutylamine 2b (Table 2, entry 7; 3ab yield 74%), N-
methylpropylamine 2c (Table 2, entry 8; 3ac yield 96%), N-ethylcyclohexylamine (Table 2, entry 9; 3ad yield 
86%), morpholine (Table 2, entry 10; 3ae yield 76%), and piperidine (Table 2, entry 11; 3af yield 93%), also 
led to excellent results. 
 
 
 
Table 2. Synthesis of N,N-dialkyl-2-(1-alkyl-1H-benzo[d]imidazo[1,2-a]imidazol-2-yl)acetamides 3 by PdI2-
Catalyzed Oxidative Aminocarbonylation-Heterocyclization-Isomerization of (1-Prop-2-ynyl-1H-
benzimidazol-2-yl)amines 1a 
 
Entry 1 2 3 
Yield of 3b 
(%) 
TONc 
1 
 
 
 
95 
 
 
285 
6 
 
2 
 
2a 
 
78 
 
 
234 
3 
 
2a 
 
79 
 
 
237 
4 
 
2a 
 
78 
 
 
234 
5 
 
2a 
 
64 
 
 
192 
6 
 
 
2a 
 
94 
 
 
282 
7d 1a 
 
 
74 
 
 
222 
8 1a 
 
 
96 
 
 
288 
7 
 
9 1a 
 
 
96 
 
 
288 
10 1a 
 
 
76 
 
 
228 
11 1a 
 
 
93 
 
 
279 
aUnless otherwise noted, all reactions were carried out in MeCN (0.1 mmol of 1 per mmol of solvent) at 100 °C for 24 h under 20 atm (at 25 °C) of 
a 4:1 mixture of CO-air, in the presence of the amine 2 (3 equiv), PdI2 (0.33 mol%), and KI (0.33 equiv).  b Isolated yield based on starting 1. d TON = 
turnover number (mol of product 3 per mole of palladium) d Reaction time was 39 h. 
 
 
As shown in Scheme 2, the key step in the formation of 3 are the PdI2-catalyzed oxidative 
monoaminocarbonylation of the terminal triple bond to give 2-ynamide intermediate I and the subsequent 
cyclization by intramolecular conjugate addition. Accordingly, a substrate bearing an internal triple bond, 
such as 1-(but-2-yn-1-yl)-N-methyl-1H-benzo[d]imidazol-2-amine 1g, was unreactive under the reaction 
conditions. To further corroborate the mechanistic hypothesis shown in Scheme 2, we tried to synthesize the 
2-ynamide compound 8 in order to assess its possible conversion into the corresponding 
benzimidazoimidazole 3ab. Thus, THP-protected propargyl alcohol 4 was subjected to oxidative 
monoaminocarbonylation conditions8 to give the corresponding N,N-dibutyl-4-hydroxybut-2-ynamide 5, 
which was easily converted into 4-bromo-N,N-dibutylbut-2-ynamide 7 by deprotection to give 6, mesylation, 
and nucleophilic substitution with LiBr (Scheme 3). When 7 was allowed to react with N-methyl-1H-
benzo[d]imidazol-2-amine, 3ab was directly obtained by in situ cyclization of the N,N-dibutyl-4-(2-
(methylamino)-1H-benzo[d]imidazol-1-yl)but-2-ynamide intermediate 8, in perfect agreement with our 
mechanistic hypothesis. 
 
8 
 
 
Scheme 3. Formation of benzimidazoimidazoles 3ab by the reaction between N-methyl-1H-
benzo[d]imidazol-2-amine and 4-bromo-N,N-dibutylbut-2-ynamide 7. 
 
 
In conclusion, we have reported a multicomponent approach to the direct synthesis of functionalized 
benzimidazoimidazole derivatives, that are, N,N-dialkyl-2-(1-alkyl-1H-benzo[d]imidazo[1,2-a]imidazol-2-
yl)acetamides 3, starting from readily available N-substituted-1-(prop-2-yn-1-yl)-1H-benzo[d]imidazol-2-
amines 1 and nucleophilic secondary amines 2, by a sequential PdI2/KI-catalyzed oxidative 
aminocarbonylation-intramolecular conjugate addition-isomerization process. Reactions were carried out 
under relatively mild conditions (100 °C under 20 atm of a 4:1 mixture of CO-air), and led to the selective 
formation of polyheterocycles 3 starting from differently substituted substrates 1 and different amines 2, 
with good to excellent isolated yields (64-96%) and high turnover numbers (192-288 mol of product per mol 
of palladium employed). Our method provides a new convenient entry to an important class of 
polyheterocycles, with important potential pharmacological properties. 
 
 
 
Experimental Section 
 General Experimental Methods. Melting points are uncorrected. 1H NMR and 13C NMR spectra were 
recorded at 25 °C in CDCl3 or DMSO-d6 or CD3OD at 300 or 500 MHz and 75 or 125 MHz, respectively, with 
Me4Si as internal standard. Chemical shifts () and coupling constants (J) are given in ppm and in Hz, 
respectively. IR spectra were taken with an FT-IR spectrometer. Mass spectra were obtained using a GC-MS 
apparatus at 70 eV ionization voltage Microanalyses were carried out at our analytical laboratory. All 
reactions were analyzed by TLC on silica gel 60 F254 or on neutral alumina and by GLC using a gas 
chromatograph and capillary columns with polymethylsilicone + 5% phenylsilicone as the stationary phase or 
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using a gas chromatograph and a capillary columns with diethyl tertbutylsilyl-β-cyclodextrine as the 
stationary phase. Column chromatography was performed on silica gel 60 (70-230 mesh). Evaporation refers 
to the removal of solvent under reduced pressure. 
Substrates 1a-f were prepared as we already reported.6 Substrate 1g was prepared in as similar way, as 
described below. All other materials were commercially available and were used without further purification. 
Preparation of 1-(But-2-yn-1-yl)-N-methyl-1H-benzo[d]imidazol-2-amine 1g 
To a cooled (0°C) solution of N-methyl-1H-benzo[d]imidazol-2-amine6 (2.00 g, 13.6 mmol) in anhydrous DMF 
(24 mL), was added portionwise, under nitrogen, sodium hydride (95%, 13.6 mmol, 344 mg). The mixture 
was then stirred at room temperature for 1 h. 1-Bromo-2-butyne (2.0 g, 15.0 mmol) was added and stirring 
continued for 15 h. Water (100 mL) and chloroform (100 mL) were added, and phases were separated. The 
aqueous phase was washed with chloroform (2×50 mL). The collected organic phases were finally washed 
with brine (50 mL) and dried over sodium sulfate. After filtration and evaporation of the solvent, the crude 
product was purified by column chromatography on silica gel using 7:3 CHCl3-acetone as eluent. Yield: 1.73 
g, starting from 2.00 g N-methyl-1H-benzo[d]imidazol-2-amine (64%); colorless solid; mp = 173-176 °C. IR 
(KBr): ν = 2226 (vw), 1620 (m), 1603 (m), 1574 (s), 1466 (m), 1454 (m), 1416 (m), 1386 (w), 1344 (w), 1283 
(w), 1260 (w), 1238 (m), 1084 (w), 1015 (w), 731 (s) cm-1. 1H NMR (300 MHz, CD3OD): δ = 7.32-7.25 (m, 1 H, 
aromatic), 7.17-7.10 (m, 1 H, aromatic), 7.08-6.95 (m, 2 H, aromatic), 4.64 (q, J = 2.3, 2 H, CH2C≡), 3.02 (s, 3 
H, NCH3), 1.74 (t, J = 2.3, 3 H, ≡CCH3). (Note: the NH signal was too broad to be detected). 13C NMR (75 MHz, 
CD3OD): δ = 156.7, 143.2, 135.3, 122.4, 120.8, 116.3, 108.9, 81.8, 73.5, 32.7, 30.0, 2.9. GC-MS: m/z = 199 (M+, 
100), 198 (36), 184 (16), 169 (3), 157 (3), 146 (93), 129 (12), 119 (45), 118 (41), 102 (4), 92 (16), 90 (17), 77 
(12). Anal. calcd for C12H13N3 (199.26): C, 72.33; H, 6.58; N, 21.09; found C, 72.48; H, 6.56; N, 21.02. 
 
 General Procedure for the Synthesis of 2-(1-Alkyl-1H-benzo[d]imidazo[1,2-a]imidazol-2-yl)acetamides 
3  
 A 250 mL stainless steel autoclave was charged in the presence of air with PdI2 (1.1 mg, 3.05  10–3 mmol), 
KI (50.0 mg, 0.301 mmol), anhydrous CH3CN (9.2 mL), (1-prop-2-ynyl-1H-benzoimidazol-2-yl)amine 1 (0.92 
mmol) [1a: 170 mg; 1b: 196 mg; 1c: 234 mg; 1d: 196 mg; 1e: 240 mg; 1f: 222 mg], and amine 2 (2.76 mmol) 
[2a: 202 mg; 2b: 356 mg; 2c: 240 mg; 2d: 235 mg; 2e: 351 mg; 2f: 202mg]. The autoclave was sealed and, 
while the mixture was stirred, the autoclave was pressurized with CO (16 atm) and air (up to 20 atm). After 
being stirred at 100 °C for 24-39 h (see Table 2), the autoclave was cooled, degassed and opened. After 
evaporation of the solvent, products 3 were purified by column chromatography on silica gel using 7:3 CHCl3-
acetone (3aa, 3ca, 3da, 3ea, 3fa, 3ac, 3ad, 3ae, 3af) or 9:1 CHCl3-acetone (3ba) or 8:2 hexane - acetone (3ab) 
as eluent.  
 
 N,N-diethyl-2-(1-methyl-1H-benzo[d]imidazo[1,2-a]imidazol-2-yl)acetamide (3aa). Yield: 249 mg, starting 
from 170 mg of 1a (95%). Colorless solid, mp: 137 – 139°C; IR (KBr): v = 1638 (s), 1587 (s), 1563 (s), 1444 (s), 
980 (m), 949 (m), 926 (m), 910 (m), 847 (m), 793 (m), 706 (s), 652 (m) cm-1; 1H-NMR (300 MHz, CD3OD): δ 
=7.59-7.51 (m, 2 H, aromatic), 7.27 (s, br, 1 H, =CH), 7.26-7.20 (m, 1 H, aromatic), 7.11-7.04 (m, 1 H, aromatic), 
3.64 (d, br, J = 0.5, 2 H, CH2CO), 3.47 (s, 3 H, NCH3), 3.46-3.33 (m, 4 H, 2 CH2CH3), 1.24 (t, J = 7.2, 3 H, CH2CH3), 
1.11 (t, J = 7.1, 3 H, CH2CH3); 13C NMR (75 MHz, CD3OD): δ = 169.7, 153.0, 147.2, 128.8, 128.5, 123.8, 119.6, 
118.0, 111.3, 105.2, 43.6, 42.0, 30.4, 29.8, 14.5, 13.2; GC/MS = 284 (M+, 99), 211 (26), 184 (93), 169 (7), 129 
(12), 100 (100), 72 (59); anal. calcd for C16H20N4O (284.36): C , 67.58; H, 7.09, N, 19.70; found C, 67.44, H, 
7.11, N, 19.76. 
 
 N,N-diethyl-2-(1,6,7-trimethyl-1H-benzo[d]imidazo[1,2-a]imidazol-2-yl)acetamide (3ba). Yield: 224 mg, 
starting from 196 mg of 1b (78%). Yellow solid, mp: 140-142°C; IR (KBr): v = 1636 (s), 1589 (s), 1558 (s), 1385 
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(m), 1323 (m), 1217 (m), 1155 (m), 1088 (w), 1001 (w), 853 (s), 845 (m), 729 (m) cm-1; 1H NMR (500 MHz, 
CDCl3): δ = 7.37 (s, 1 H, aromatic), 7.27 (s, 1 H, aromatic), 7.20 (s, 1 H, =CH), 3.77 (s, br, 2 H, CH2CO), 3.65 (s, 
3 H, NCH3), 3.47-3.38 (m, 4 H, 2 CH2CH3), 2.343 (s, 3 H, CH3 on aromatic ring), 2.337 (s, 3 H, CH3 on aromatic 
ring), 1.27 (t, J = 7.3, 3 H, CH2CH3), 1.15 (t, J = 7.3, 3 H, CH2CH3); 13C NMR (125 MHz, CDCl3): δ = 166.9, 149.3, 
141.3, 132.3, 128.4, 127.3, 124.8, 117.0, 110.8, 104.5, 42.6, 40.9, 30.7, 30.3, 20.4, 20.2, 14.5, 13.0; GC/MS = 
312 (M+, 62), 297 (2), 239 (18), 212 (100), 197 (6), 157 (5), 142 (2), 100 (37), 91 (2); anal. calcd for C18H24N4O 
(312.42): C, 69.20; H, 7.74; N 17.93; found C, 69.10; H, 7.75; N 17.94. 
 
 2-(6,7-Dichloro-1-methyl-1H-benzo[d]imidazo[1,2-a]imidazol-2-yl)-N,N-diethylacetamide (3ca). Yield: 257 
mg, starting from 234 mg of 1c (79%). Yellow solid, mp: 155 - 160°C; IR (KBr): v = 1655 (s), 1618 (s), 1591 (s), 
1555 (s), 1460 (s), 1406 (m), 1267 (m), 1088 (m), 851 (m), 826 (w) cm-1; 1H NMR (300 MHz, CD3OD) δ = 7.78 
(s, 1 H, aromatic), 7.55 (s, 1 H, aromatic), 7.39 (s, 1 H, =CH), 3.91 (s, 2 H, CH2CO), 3.55 (s, 3 H, NCH3), 3.54 (q, 
J = 7.1, 2 H, NCH2CH3), 3.43 (q, J = 7.1, 2 H, NCH2CH3), 1.31 (t, J = 7.2, 3 H, CH2CH3), 1.16 (t, J = 7.1, 3 H, CH2CH3); 
13C NMR (75 MHz, CD3OD) δ = 169.6, 154.0, 146.5, 129.9, 127.6, 127.2, 122.5, 118.8, 113.0, 105.8, 43.8, 42.0, 
30.6, 30.1, 14.5, 13.3; GC/MS = 354 [(M +2)+, 9], 353 [(M+1)+, 3], 352 (M+, 17), 252 (13), 217 (5), 189 (3), 100 
(100); anal. calcd for C16H18Cl2N4O (353.25): C, 54.40; H, 5.14; Cl, 20.07; N, 15.86; found C 54.45, H, 5.13; Cl, 
20.09; N, 15.84; S, 9.59. 
 
 N,N-diethyl-2-(1-propyl-1H-benzo[d]imidazo[1,2-a]imidazol-2-yl)acetamide (3da). Yield: 225 mg, starting 
from 196 mg of 1d (78%). Yellow solid, mp: 98-99°C. IR (KBr): v = 1636 (s), 1586 (w), 1560 (m), 1431 (m), 1396 
(m), 1358 (w), 1256 (m), 1233 (m), 1132 (m), 760 (m), 745 (w) cm-1; 1H NMR (300 MHz, CDCl3): δ = 7.72-7.64 
(m, 1 H, aromatic), 7.53-7.46 (m, 1 H, aromatic), 7.31-7.20 (m, 1 H, aromatic), 7.15-7.04 (m, 2 H, 1 H aromatic 
+ =CH), 4.05-3.95 (m, 2 H, NCH2CH2CH3), 3.69 (d, J = 1.0, 2 H, CH2CO), 3.50-3.35 (m, 4 H, 2 NCH2CH3), 1.92 
(hexuplet, J = 7.5, 2 H, NCH2CH2CH3), 1.23 (t, J = 7.2, 3 H, Me), 1.17 (t, J = 7.1, 3 H, Me), 0,98 (t, J = 7.5, 3 H, 
Me); 13C NMR (125 MHz, CDCl3): δ = 166.9, 151.9, 146.9, 127.3, 126.2, 122.5, 118.1, 118.0, 109.7, 103.4, 45.4, 
42.6, 40.9, 30.6, 22.6, 14.5, 13.0, 11.2; GC/MS = 312 (M+, 65), 297 (6), 283 (5), 269 (4), 255 (2), 240 (14), 212 
(48), 198 (30), 185 (18), 171 (56), 157 (3), 144 (15), 129 (21), 100 (87), 72 (100); anal. calcd for C18H24N4O 
(312.42): C, 69.20; H, 7.74; N 17.93; found C, 69.35; H, 7.72; N 17.90. 
 
 2-(1-Benzyl-1H-benzo[d]imidazo[1,2-a]imidazol-2-yl)-N,N-diethylacetamide (3ea). Yield: 212 mg, starting 
from 240 mg of 1e (64%). Yellow solid, mp: 57-59°C; IR (film): v = 1643 (s), 1589 (m), 1566 (m), 1470 (w), 1454 
(m), 1238 (m), 1136 (m), 743 (m) cm-1; 1H NMR (300 MHz, CDCl3): δ = 7.69 (d, br, J = 8.1, 1 H, aromatic), 7.51 
(d, br, J = 7.9, 1 H, aromatic), 7.32–7.15 (m, 7 H, 6 H aromatic + =CH), 7.13-7.05 (m, 1 H, aromatic), 5.36 (s, 2 
H, CH2Ph), 3.45 (s, br, 2 H, CH2CO), 3.36 (q, J = 7.1, 2 H, NCH2), 3.09 (q, J = 7.2, 2 H, NCH2), 1.13 (t, J = 7.1, 3 H, 
Me), 0.99 (t, J = 7.1, 3 H, Me); 13C NMR (75 MHz, CDCl3): δ = 166.8, 152.5, 146.8, 136.5, 128.9, 127.9, 127.4, 
126.9, 126.4, 122.5, 118.2, 118.0, 109.8, 104.1, 47.1, 42.4, 40.7, 30.5, 14.1, 13.0; GC/MS = 360 (M+, 55), 287 
(27), 260 (39), 246 (3), 198 (13), 170 (32), 129 (19), 100 (44), 91 (100), 72 (59); anal. calcd for C22H24N4O 
(360.46): C, 73.31; H, 6.71; N 15.54; found C, 73.45; H, 6.70; N 15.51. 
 
 N,N-diethyl-2-(1-isopentyl-1H-benzo[d]imidazo[1,2-a]imidazol-2-yl)acetamide (3fa). Yield: 294 mg, 
starting from 222 mg of 1f (94%). Colorless solid, mp: 52-54°C; IR (film): v = 1634 (s), 1586 (m), 1562 (m), 
1557 (m), 1454 (m), 1435 (m), 1381 (m), 1365 (w), 1256 (m), 1229 (m), 1136 (m), 1098 (w), 797 (s) cm-1; 1H 
NMR (300 MHz, CDCl3): δ = 7.65 (d, br, J = 7.9, 1 H, aromatic), 7.45 (d, br, J = 7.9, 1 H, aromatic), 7.25-7.17 
(m, 1 H, aromatic), 7.07-6.99 (m, 1 H, aromatic), 7.05 (s, 1 H, =CH), 4.03-3.94 (m, 2 H, NCH2), 3.61 (s, br, 2 H 
CH2CO), 3.45-3.29 (m, 4 H, 2 NCH2CH3), 1.78-1.57 (m, 3 H, NCH2CH2CH), 1.19 (t, J = 7.1, 3 H, NCH2CH3), 1.13 
(t, J = 7.1, 3 H, NCH2CH3), 0.94 [d, J = 6.4, 6 H, CH(CH3)2]; 13C NMR (75 MHz, CDCl3): δ = 166.8, 151.9, 147.0, 
127.3, 126.0, 122.4, 118.0, 117.9, 109.7, 103.4, 42.5, 42.3, 40.8, 37.9, 30.5, 26.1, 22.5, 14.5, 13.0; GC/MS = 
340 (M+, 100), 325 (56), 311 (5), 297 (5), 284 (9), 269 (26), 255 (11), 241 (25), 240 (28), 226 (20), 212 (13), 
198 (18), 197 (17), 185 (97), 184 (46), 170 (44), 138 (18), 137 (18), 129 (10), 100 (24), 72 (34); anal. calcd for 
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C20H28N4O (340.47): C, 70.56; H, 8.29; N 16.46; found C, 70.49; H, 8.31; N 16.47. 
 
 N,N-dibutyl-2-(1-methyl-1H-benzo[d]imidazo[1,2-a]imidazol-2-yl)acetamide (3ab).Yield: 232 mg, starting 
from 170 mg of 1a (74%). Yellow solid, mp: 60-62°C; IR (KBr): v = 1649 (s), 1591 (m), 1566 (m), 1344 (m), 1321 
(m), 1281 (w), 1238 (m), 1140 (m), 924 (w), 858 (m), 827 (m), 738 (m) cm-1; 1H NMR (300 MHz, CDCl3) δ = 
7.68-7.62 (m, 1 H, aromatic), 7.48-7.43 (m, 1 H, aromatic), 7.28-7.21 (m, 1 H, aromatic), 7.11-7.02 (m, 1 H, 
aromatic), 7.03 (s, br, 1 H, =CH), 3.58 (s, 3 H, NCH3), 3.53 (d, br, J = 0.6, 2 H, CH2CO), 3.37-3.23 (m, 4 H, 2 
NCH2), 1.65-1.45 (m, 4 H, 2 NCH2CH2), 1.45-1.24 (m, 4 H, 2 CH2CH3), 0.98 (t, J = 7.3, 3 H, Me), 0.92 (t, J = 7.3, 
3 H, Me); 13C NMR (75 MHz, CDCl3) δ = 167.2, 152.1, 146.7, 127.4, 126.6, 122.4, 118.0, 117.8, 109.7, 103.3, 
48.1, 46.2, 31.2, 30.1, 29.8, 29.69, 29.58, 20.2, 20.1, 13.8; GC/MS = 340 (M+, 67), 297 (2), 211 (25), 184 (48), 
156 (30), 129 (7), 100 (33), 90 (3), 57 (100); anal. calcd for C20H28N4O (340.47): C, 70.56; H, 8.29; N 16.46; 
found C, 70.63; H, 8.30; N 16.41. 
 
 N-methyl-2-(1-methyl-1H-benzo[d]imidazo[1,2-a]imidazol-2-yl)-N-propylacetamide (3ac). (Mixture of 
diastereoisomers A+B, deriving from hindered rotation around the (CO)-N amide bond; A/B ca. 1.5, by 1H 
NMR). Yield: 251 mg, starting from 170 mg of 1a (96%). Colorless solid, mp: 67-70°C; IR (KBr): v = 1643 (s), 
1589 (w), 1566 (w), 1470 (m), 1454 (m), 1402 (w), 1238 (m), 1136 (m), 800 (m) cm-1; 1H NMR (300 MHz, 
DMSO-d6) δ = 7.77-7.66 [m, 1 H (A) + 1 H (B), aromatic], 7.56 [s, br, 1 H (A) + 1 H (B), =CH], 7.52-7.43 [m, 1 H 
(A) + 1 H (B), aromatic], 7.23-7.12 [m, 1 H (A) + 1 H (B), aromatic], 7.08-6.96 [m, 1 H (A) + 1 H (B), aromatic], 
3.93 [s, br, 2 H (A) + 2 H (B), CH2CO], 3.60–3.22 [m, 2 H (A) + 2 H (B), NCH2], 3.51 [s, br, 3 H (A) + 3 H (B), NCH3], 
3.08 [s, 3 H (A), CH3N(CO)], 2.86 [s, 3 H (B), CH3N(CO)], 1.69–1.56 [m, 2 H (B), NCH2CH2CH3), 1.56–1.43 [m, 2 
H (A), NCH2CH2CH3], 0.92 [t, J = 7.1, 3 H (B), NCH2CH2CH3], 0.83 [t, J = 7.1, 3 H (A), NCH2CH2CH3]; 13C NMR (125 
MHz, DMSO-d6): δ = 167.8 (A), 167.7 (B), 151.4 (A+B), 145.9 (A+B), 127.80 (B), 127.76 (A), 126.9 (A+B), 121.9 
(A+B), 117.4 (B), 116.8 (A), 110.3 (A+B), 103.8 (A+B), 50.7 (B), 48.6 (A), 35.0 (A), 33.0 (B), 29.7 (B), 29.2 (A), 
20.9 (B), 19.9 (A), 11.0 (A), 10.8 (B); GC/MS = 284 (M+, 97), 212 (16), 211 (15), 184 (100), 169 (8), 155 (4), 143 
(6), 129 (10), 116 (4), 100 (39), 90 (5), 77 (2); anal. calcd for C16H20N4O (284.36): C, 67.58; H, 7.09; N 19.70; 
found C, 67.69; H, 7.10; N 19.66. 
 
 N-cyclohexyl-N-ethyl-2-(1-methyl-1H-benzo[d]imidazo[1,2-a]imidazol-2-yl)acetamide (3ad). (Mixture of 
diastereoisomers A+B, deriving from hindered rotation around the (CO)-N amide bond; A/B ca. 1.1, by 1H 
NMR). Yield: 299 mg, starting from 170 mg of 1a (96%). Colorless solid, mp: 68-71°C; IR (film): v = 1643 (s), 
1589 (w), 1564 (m), 1452 (m), 1381 (w), 1240 (m), 1132 (w), 741 (m) cm-1; 1H NMR (300 MHz, CDCl3) δ =7.64 
[d, br, J = 8.1, 1 H (A) + 1 H (B), aromatic], 7.44 [d, br, J = 7.8, 1 H (A) + 1 H (B), aromatic), 7.23 [t, br, J = 7.5, 1 
H (A) + 1 H (B), aromatic), 7.05 [t, br, J = 7.5, 1 H (A) + 1 H (B), aromatic], 6.99 [s, br, 1 H (A), =CH], 6.97 [s, br, 
1 H (B), =CH], 3.52 [s, br, 3 H (B), NCH3], 3.50 [s, br, 3 H (A), NCH3], 3.45 [s, br, 2 H (A)], 3.42 [s, br, 2 H (B), 
CH2CO], 3.34–3.20 [m, 2 H (A) + 2 H (B), NCH2CH3], 1.94–1.04 [m, 14 H (A) + 14 H (B), cyclohexyl + NCH2CH3]; 
13C NMR (75 MHz, CDCl3): δ = 167.4 (B), 166.8 (A), 152.0 (A+B), 146.7 (A+B), 127.3 (A+B), 126.8 (A), 126.7 (B), 
122.3 (A+B), 117.9 (A+B), 117.6 (A+B), 109.8 (A+B), 103.2 (A), 103.1 (B), 57.6 (A+B), 54.5 (A+B), 38.4 (B), 37.0 
(A), 31.7 (A+B), 30.8 (A+B), 30.5 (A), 30.3 (B), 29.5 (A+B), 25.9 (A), 25.8 (B), 25.4 (B), 25.1 (A), 16.8 (A), 14.8 
(B); GC/MS = 338 (M+, 32), 211 (9), 184 (47), 169 (7), 154 (20), 129 (7), 116 (3), 102 (8), 83 (100), 72 (13); anal. 
calcd for C20H26N4O (338.46): C, 70.98; H, 7.74; N 16.55; found C, 70.81; H, 7.75; N 16.59. 
 
 2-(1-Methyl-1H-benzo[d]imidazo[1,2-a]imidazol-2-yl)-1-morpholinoethan-1-one (3ae). Yield: 209 mg, 
starting from 170 mg of 1a (76%). Colorless solid, mp: 189-192°C; . IR (KBr): v = 1647 (s), 1587 (w), 1562 (m), 
1420 (m), 1271 (w), 1242 (m), 1115 (m), 1038 (w), 854 (w), 741 (m) cm-1; 1H NMR (300 MHz, CDCl3) δ = 7.67 
(d, br, J = 8.0, 1 H, aromatic), 7.48 (d, J = 7.8, 1 H, aromatic), 7.32-7.22 (m, 1 H, aromatic), 7.13 - 7.03 (m, 1 H, 
1 H aromatic), 7.04 (s, br, 1 H, =CH), 3.75–3.43 (m, 8 H, morpholine ring), 3.58 (s, 3 H, NCH3), 3.51 (s, br, 2 H, 
CH2CO); 13C NMR (75 MHz, CDCl3): δ = 166.4, 152.2, 146.8, 127.3, 125.8, 122.6, 118.1, 117.9, 109.7, 103.3, 
66.7, 66.4, 46.2, 42.3, 29.9, 29.6; GC/MS = 298 (M+, 75), 212 (18), 211 (15), 184 (100), 169 (7), 155 (3), 143 
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(5), 129 (7), 114 (11), 102 (6), 70 (13); anal. calcd for C16H18N4O2 (298.35): C, 64.41; H, 6.08; N 18.78; found C, 
64.30; H, 6.06; N 18.74. 
 
 2-(1-Methyl-1H-benzo[d]imidazo[1,2-a]imidazol-2-yl)-1-(piperidin-1-yl)ethan-1-one (3af). Yield: 254 mg, 
starting from 170 mg of 1a (93%). Yellow solid, mp: 148-150°C; IR (KBr): v = 1630 (s), 1589 (m), 1566 (m), 
1456 (s), 1395 (m), 1352 (w), 1130 (s), 1016 (m), 851 (m), 820 (w), 733 (s) cm-1; 1H NMR (300 MHz, CDCl3) δ = 
7.67 (d, br, J = 8.1, 1 H, aromatic), 7.48 (d, br, J = 7.7, 1 H, aromatic), 7.31-7.22 (m, 1 H, aromatic), 7.13-7.04 
(m, 1 H, aromatic), 7.08 (s, br, 1 H, =CH), 3.64 (s, 3 H, NCH3), 3.63 (s, br, 2 H CH2CO), 3.62-3.56 (m, 2 H, NCH2), 
3.49-3.44 (m, 2 H, NCH2), 1.74-1.53 (m, 6 H, CH2CH2CH2); 13C NMR (75 MHz, CDCl3) δ = 165.9, 152.1, 146.7, 
127.3, 126.5, 122.5, 118.1, 117.9, 109.7, 103.3, 47.1, 43.3, 30.4, 29.7, 26.5, 25.5, 24.3; GC/MS = 296 (M+, 
100), 267 (1), 211 (17), 184 (98), 169 (11), 143 (8), 129 (13), 112 (97), 102 (13), 90 (7), 69 (76); anal. calcd for 
C17H20N4O (296.37): C, 68.90; H, 6.80; N 18.90; found C, 68.81; H, 6.82; N 18.96. 
 
Preparation of N,N-dibutyl-4-[(tetrahydro-2H-pyran-2-yl)oxy]but-2-ynamide 5.8 
A 250 mL stainless steel autoclave was charged in the presence of air with PdI2 (14.9 mg, 41.4 × 10–3 mmol), 
KI (686.3 mg, 4.14 mmol), and a solution of 2-(prop-2-yn-1-yloxy)tetrahydro-2H-pyran (1.74 g, 12.4 mmol) 
and dibutylamine (1.60 g, 12.4 mmol) in anhydrous dioxane (25 mL). The autoclave was sealed and, while the 
mixture was stirred, the autoclave was pressurized with CO (16 atm) and air (up to 20 atm). After being stirred 
at 100 °C for 24 h, the autoclave was cooled, degassed and opened. After evaporation of the solvent, the 
crude mixture was purified by column chromatography on silica gel using as eluent 9:1 hexane- AcOEt to give 
N,N-dibutyl-4-[(tetrahydro-2H-pyran-2-yl)oxy]but-2-ynamide as a colorless oil. Yield: 1.85 g, starting from 
1.74 g 2-(prop-2-yn-1-yloxy)tetrahydro-2H-pyran (50%). IR (film): ν = 2957 (m), 2934 (m), 2872 (w), 2241 (vw), 
1630 (s), 1466 (m), 1458 (m), 1427 (w), 1377 (w), 1294 (w), 1227 (w), 1202 (w), 1121 (m), 1028 (m), 903 (w) 
cm-1. 1H NMR (300 MHz, CDCl3): δ = 4.82 (t, J = 3.0, 1 H, OCH), 4.41 (s, 2 H, CH2C≡), 3.89-3.78 (m, 1 H, OCHH), 
3.56-3.47 (m, 2 H, NCH2), 3.40-3.30 (m, 2 H, NCH2), 3.22-3.12 (m, 2 H, OCHH), 1.88 – 1.23 (m, 14 H, 
OCH2CH2CH2CH2 + 2 NCH2CH2CH2), 0.96 (t, J = 7.3, 3 H, Me), 0.93 (t, J = 7.3, 3 H, Me). 13C NMR (75 MHz, CDCl3): 
δ = 153.7, 97.0, 86.6, 79.0, 62.0, 53.9, 48.8, 44.5, 31.0, 30.2, 29.5, 25.3, 20.2, 19.9, 18.9, 13.9, 13.8. GC-MS: 
m/z = 295 (M+, absent), 252 (10), 212 (5), 194 (10), 180 (7), 168 (15), 151 (19), 140 (13), 128 (25), 124 (12), 
109 (65), 94 (13), 85 (100), 81 (26), 67 (54), 57 (49), 55 (46). Anal. calcd for C17H29NO3 (295.42): C, 69.12; H, 
9.89; N, 4.74; found C, 69.25; H, 9.88; N, 4.75. 
 
Preparation of N,N-dibutyl-4-hydroxybut-2-ynamide 6 
A mixture of N,N-dibutyl-4-[(tetrahydro-2H-pyran-2-yl)oxy]but-2-ynamide (1.5 g, 5.08 mmol) and PPTS (0.65 
g, 2.59 mmol) in anhydrous EtOH (16 mL) was stirred under nitrogen for 15 h at 55°C. Ethanol was removed, 
then water (20 mL) and CHCl3 (20 mL) were added and the phases were separated. The aqueous phase was 
extracted with CHCl3 (10 mL), and the collected organic phases were dried on Na2SO4. After filtration and 
evaporation of the solvent, the crude product was purified by column chromatography on silica gel using as 
eluent 1:1 hexane-acetone. Yield: 0.86 g, starting from 1.5 g 2-(prop-2-yn-1-yloxy)tetrahydro-2H-pyran 
(80%); colorless oil. IR (KBr): ν = 3381 (m, br), 2959 (m), 2932 (m), 2872 (m), 2245 (w), 2226 (w), 1620 (s), 
1464 (m), 1454 (m), 1433 (m), 1377 (w), 1296 (w), 1229 (m), 1159 (w), 1034 (m), 737 (m) cm-1. 1H NMR (300 
MHz, CDCl3): δ = 4.42 (s, 2 H, CH2OH), 3.52 (t, J = 7.3, 2 H, NCH2), 3.34 (t, J = 7.4, 2 H, NCH2), 1.65-1.45 (m, 4 
H, 2 NCH2CH2), 1.42-1.23 (m, 4 H, 2 CH2CH3), 0.95 (t, J = 7.6, 3 H, Me), 0.92 (t, J = 7.6, 3 H, Me). 13C NMR (75 
MHz, CDCl3): δ = 154.4, 89.8, 78.6, 50.8, 49.1, 44.8, 31.2, 29.8, 20.3, 20.0, 13.7. GC-MS: m/z = 211 (M+, 1), 196 
(5), 180 (3), 168 (36), 154 (4), 151 (8), 150 (8), 136 (8), 126 (65), 114 (15), 109 (6), 94 (8), 86 (51), 83 (100), 79 
(12). Anal. calcd for C12H21NO2 (211.31): C, 68.21; H, 10.02; N, 6.63; found C, 68.33; H, 10.00; N, 6.64. 
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Preparation of 4-Bromo-N,N-dibutylbut-2-ynamide 7 
To a solution of N,N-dibutyl-4-hydroxybut-2-ynamide (0.76 g, 3.6 mmol) and NEt3 (0.37 g, 3.66 mmol) in 
anhydrous CH2Cl2 (20 mL), mantained under nitrogen and cooled in ice, was added dropwise MsCl (0.5 g, 4.36 
mmol). The solution was stirred for 1 h at room temperature and then water was added (15 mL). The phases 
were separated, and the organic layer was washed with HCl (2M, 10 ml) followed by brine (10 mL) and 
saturated NaHCO3 (10 mL). After drying over Na2SO4 and filtration, the solvent was removed and the crude 
mesylate was introduced under nitrogen in a flask containing anhydrous acetone (23 mL) and LiBr (1 g, 11.5 
mmol). After refluxing for 1 h, the mixture was cooled, and the precipitate was filtered off. Acetone was 
removed by evaporation, and water was added to the residue (20 mL). The mixture was then extracted with 
light petroleum (b.p. 40-60) (2 × 10 mL) and dried over Na2SO4. After filtration and evaporation of the solvent, 
the crude product was purified by column chromatography on silica gel using as eluent 9:1 hexane-AcOEt. 
Yield: 0.47 g, starting from 0.76 g N,N-dibutyl-4-hydroxybut-2-ynamide (65%); colorless oil. IR (KBr): ν = 2959 
(m), 2932 (m), 2872 (w), 2226 (vw), 1628 (s), 1466 (m), 1427 (m), 1377 (w), 1294 (w), 1227 (m), 733 (w) cm -
1. 1H NMR (300 MHz, CDCl3): δ = 4.03 (s, 2 H, CH2Br), 3.53-3.46 (m, 2 H, NCH2), 3.38-3.31 (m, 2 H, NCH2), 1.66-
1.46 (m, 4 H, 2 NCH2CH2), 1.44-1.24 (m, 4 H, 2 CH2CH3), 0.97 (t, J = 7.3, 3 H, CH3), 0.92 (t, J = 7.3, 3 H, CH3). 13C 
NMR (75 MHz, CDCl3): δ = 153.2, 84.7, 79.3, 48.8, 44.6, 31.0, 29.5, 20.2, 19.9, 13.8, 12.9. GC-MS: m/z = 275 
[(M+2)+, 1], 273 (M+, 1), 232 (32), 230 (34), 194 (69), 190 (29), 188 (29), 176 (3), 166 (5), 152 (44), 147 (36), 
145 (36), 138 (8), 128 (8), 110 (7), 95 (17), 86 (100), 81 (12). Anal. calcd for C12H20BrNO (274.20): C, 52.56; H, 
7.35;Br, 29.14; N, 5.11; found C, 52.40; H, 7.36; Br, 29.17  N, 5.09. 
 
Reaction Between 4-Bromo-N,N-dibutylbut-2-ynamide 4 and N-methyl-1H-benzo[d]imidazol-2-amine 
Leading to Benzimidazimidazole 3ab 
To a cooled (0°C) solution of N-methyl-1H-benzo[d]imidazol-2-amine6 (0.27 g, 1.83 mmol) in anhydrous DMF 
(2.1 mL), was added portionwise, under nitrogen, sodium hydride (95%, 1.83 mmol, 46 mg). The mixture was 
then stirred at room temperature for 1 h. 4-Bromo-N,N-dibutylbut-2-ynamide (0.5 g, 1.83 mmol) was added, 
and stirring continued for 15 h. Water (10 mL) and chloroform (10 mL) were added, and phases were 
separated. The aqueous phase was washed with chloroform (2×10 mL). The collected organic phases were 
finally washed with brine (10 mL) and dried over Na2SO4. After filtration, evaporation of the solvent and 
column chromatography on silica gel (8:2 CHCl3-acetone), N,N-dibutyl-2-(1-methyl-1H-benzo[d]imidazo[1,2-
a]imidazol-2-yl)acetamide 3ab was obtained in 40 % yield (0.249 g). 
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